Get the Stockscreener App
4.2299
0.88%
-0.0701
Evolus Inc stock is traded at $4.2299, with a volume of 84,946.
It is down -0.88% in the last 24 hours and down -26.14% over the past month.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
See More
Previous Close:
$4.30
Open:
$4.41
24h Volume:
84,946
Relative Volume:
0.07
Market Cap:
$273.86M
Revenue:
$202.09M
Net Income/Loss:
$-61.69M
P/E Ratio:
-3.9166
EPS:
-1.08
Net Cash Flow:
$-35.64M
1W Performance:
-3.36%
1M Performance:
-26.14%
6M Performance:
-33.41%
1Y Performance:
-70.11%
1-Day Range:
$4.20
$4.445
1-Week Range:
$4.0913
$4.61
52-Week Range:
$4.0913
$17.12
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
4.225 | 278.73M | 202.09M | -61.69M | -35.64M | -1.08 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.40 | 57.75B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.90 | 56.70B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.19 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.17 | 39.96B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
475.21 | 20.49B | 3.13B | 1.27B | 1.12B | 26.39 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Downgrade | Needham | Buy → Hold |
| Apr-17-25 | Initiated | BTIG Research | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
What Catalysts Are Rewriting The Evolus (EOLS) Story After The Guidance Reset - Yahoo Finance
Mizuho Lowers Price Target on Evolus, Inc. (EOLS) to $15, Maintains Outperform Rating - Insider Monkey
CEO Change: Is Evolus Inc undervalued by DCF analysis2025 Trade Ideas & AI Driven Price Forecasts - baoquankhu1.vn
Aug Patterns: Is Evolus Inc showing insider buyingMarket Trend Report & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Evolus, Inc. (NASDAQ:EOLS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
What is HC Wainwright's Forecast for Evolus FY2026 Earnings? - MarketBeat
HC Wainwright Forecasts Evolus' Q4 Earnings (NASDAQ:EOLS) - MarketBeat
Mizuho lowers Evolus stock price target to $15 on guidance reset - Investing.com Canada
Aug Opening: What hedge funds are buying Evolus IncWatch List & AI Optimized Trade Strategies - baoquankhu1.vn
Volatility Watch: What is the earnings history of Evolus IncPortfolio Update Report & Safe Entry Zone Tips - baoquankhu1.vn
H.C. Wainwright lowers Evolus stock price target to $13 on aesthetics headwinds - Investing.com Canada
HC Wainwright Lowers Evolus (NASDAQ:EOLS) Price Target to $13.00 - MarketBeat
Evolus, Inc. (EOLS) Stock Analysis: Unveiling A Compelling 264.81% Upside Potential - DirectorsTalk Interviews
Botulinum Toxin Market to Grow Strongly Through 2030 | Aesthetic - openPR.com
How A New Price Target Is Shaping The Evolus (EOLS) Story - Yahoo Finance
Evolus (NASDAQ:EOLS) Given New $13.00 Price Target at BTIG Research - MarketBeat
EOLS: BTIG Lowers Price Target While Maintaining Buy Rating | EO - GuruFocus
Understanding Momentum Shifts in (EOLS) - Stock Traders Daily
BTIG lowers Evolus stock price target to $13 on aesthetic market decline - Investing.com Nigeria
Evolus projects robust 2025 growth with upcoming product launches - MSN
Panic Selling: Should you avoid Evolus Inc stock right nowEarnings Performance Report & Capital Efficient Trade Techniques - baoquankhu1.vn
Lacklustre Performance Is Driving Evolus, Inc.'s (NASDAQ:EOLS) 30% Price Drop - 富途牛牛
VIX Spike: Is Evolus Inc undervalued by DCF analysis2025 Market WrapUp & Safe Entry Trade Reports - baoquankhu1.vn
Stifel Analyst Lowers Price Target on Evolus (EOLS) to $17.00 | - GuruFocus
Stifel lowers Evolus stock price target to $17 on tempered growth outlook - Investing.com Australia
Stifel lowers Evolus stock price target to $17 on tempered growth outlook By Investing.com - Investing.com South Africa
Evolus, Inc. (NASDAQ:EOLS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Avoiding Lag: Real-Time Signals in (EOLS) Movement - Stock Traders Daily
Evolus reports 15% Q4 growth, projects 2026 profitability By Investing.com - Investing.com Nigeria
Evolus sees FY26 revenue $327M-$337M, consensus $351.66M - TipRanks
Evolus sees Q4 revenue $88.6M-$90.6M, consensus $90.91M - TipRanks
Evolus, Inc. (EOLS) Stock Analysis: Unpacking a 222% Potential Upside in the Aesthetic Market - DirectorsTalk Interviews
EOLS: HC Wainwright & Co. Reiterates Buy Rating with $20 Price T - GuruFocus
Evolus' (EOLS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Evolus (EOLS) Projects Strong Revenue Growth Through 2028 - GuruFocus
EOLS Projects Strong Revenue Growth with Key Product Line - GuruFocus
Evolus (EOLS) Achieves Sixth Year of Double-Digit Growth in 2025 - GuruFocus
EOLS Projects Optimistic Growth with Strategic Market Expansion - GuruFocus
Evolus outlook FY sales USD 327-337 million - marketscreener.com
Evolus reports 15% Q4 growth, projects 2026 profitability - Investing.com
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue - Business Wire
How Evolus Inc. stock valuations compare to rivalsMarket Growth Review & Stock Timing and Entry Methods - Улправда
Does Evolus Inc. stock trade at a discount to peersChart Signals & Reliable Breakout Forecasts - Улправда
Why Evolus Inc. stock is favored by top institutions2025 Performance Recap & Expert Curated Trade Setup Alerts - Улправда
Can Evolus Inc. stock deliver strong Q4 earningsSwing Trading Ideas & Small Budget Portfolio Growth - Улправда
Insider Sellers Might Regret Selling Evolus Shares at a Lower Price Than Current Market Value - simplywall.st
Mizuho cuts Evolus (EOLS) estimates for Jeuveau/Evolysse on waning consumer sentiment and inflationary pressure on elective aesthetics - MSN
Will Evolus Inc. (EVL) stock benefit from sector leadershipRisk Mitigation Techniques & Low Entry Cost Investments - ulpravda.ru
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR) and Evolus (EOLS) - The Globe and Mail
Discipline and Rules-Based Execution in EOLS Response - Stock Traders Daily
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
9.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):